Invirase saquinavir data

University researchers published results in the New England Journal of Medicine of a Phase II, 24-week study in 302 AIDS patients given two-drug and three-drug regimens.

The combination of Roche's saquinavir protease inhibitor (1,800 mg/day) and Hivid zalcitabine nucleoside drug (2.25 mg/day) plus Glaxo-Wellcome's zidovudine AZT (600 mg/day), was more effective than AZT plus either saquinavir or zalcitabine. Patients had CD4 counts of 50-300 at entry. ...